drugset / Trial / NCT07445217

Predictive Validity of the Personal and Social Performance Scale for PANSS Outcomes in Schizophrenia

NCT07445217

Phase 2 Completed 763 enrolled Calo Psychiatric Center
NaSingle-groupOpen-labelTreatment

Summary

The Positive and Negative Syndrome Scale (PANSS) is a widely used instrument for assessing symptom severity in schizophrenia, whereas the Personal and Social Performance Scale (PSP) provides a practical measure of functional outcomes. This study aimed to evaluate the predictive validity of the PSP for PANSS outcomes in individuals with schizophrenia. A total of 763 patients diagnosed with schizophrenia and receiving paliperidone treatment were recruited in a 12-week multicenter prospective study. Among participants with a baseline PANSS score greater than 90, those with a 12-week PSP score above 60 were more likely to achieve a reduction of more than 20% in PANSS scores, whereas those with a PSP score below 60 showed less improvement.

Timeline

Start
2008-03-10
Primary completion
2008-06-01
Completion
2008-09-04

Publications

  • Results References 1. Lopez-Munoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005; 17: 113-135. 2. Juckel G, Morosini PL. The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Curr Opin Psychiatry. 2008; 21: 630-639. 3. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13: 261-276. 4. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988; 23: 99-110. 5. Lim K, Peh OH, Yang Z, Rekhi G, Rapisarda A, See YM, Rashid NAA, Ang MS, Lee SA, Sim K, Huang H, Lencz T, Lee J, Lam M. Large-scale evaluation of the Positive and Negative Syndrome Scale (PANSS) symptom architecture in schizophrenia. Asian J Psychiatry. 2021; 62: 102732. 6. Jelastopulu E, Giourou E, Merekoulias G, Mestousi A, Moratis E, Alexopoulos EC. Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Sydrome Scale (PANSS) in a Greek sample of patients with schizophrenia. BMC Psychiatry. 2014; 14: 197. 7. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000; 101: 323-329. 8. Lung FW, Shu BC, Kao WT, Chen CN, Ku YC, Tzeng DS. Association of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: a case-control study. BMC Med Genet. 2009; 10: 147. 9. Tzeng DS, Lian LC, Chang CU, Yang CY, Lee GT, Pan P, Lung FW. Healthcare in schizophrenia: effectiveness and progress of a redesigned care network. BMC Health Serv Res. 2007; 7: 129. 10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. American Psychiatric Assoc
  • Cheng KD, Lung FW. Predictive validity of the personal and social performance scale for PANSS outcomes in schizophrenia: a severity-stratified study. BMC Res Notes. 2026 Mar 21;19(1):197. doi: 10.1186/s13104-026-07773-y.

Drugs

EvaluationDrugModalityDoseRoute
Subject Paliperidone Unknown

Indications

No indication recorded.